Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/3881
Full metadata record
DC FieldValue
dc.contributor.authorAndrade, Sonia Gumes
dc.contributor.authorMesquita, Igor Marcelo Oliveira
dc.contributor.authorJambeiro, Jamile F.
dc.contributor.authorSantos, Isis Fernandes Magalhães
dc.contributor.authorPortella, Renata Siqueira
dc.date.accessioned2012-05-04T18:57:36Z
dc.date.available2012-05-04T18:57:36Z
dc.date.issued2003
dc.identifier.citationANDRADE, S.G. et al. Treatment with benznidazole in association with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi: investigation into the possible development of neoplasias. Revista da Sociedade Brasileira de Medicina Tropical, v. 36, n. 4, p. 441-447, jul.-aug. 2003.
dc.identifier.issn0037-8682
dc.identifier.urihttps://www.arca.fiocruz.br/handle/icict/3881
dc.language.isoeng
dc.rightsopen access
dc.subject.otherTrypanosoma cruzi
dc.subject.otherInfecção Experimental
dc.subject.otherQuimioterapia
dc.subject.otherBenzonidazol
dc.subject.otherDrogas Imunossupressoras
dc.subject.otherLinfoma não Hodgkin
dc.titleTreatment with benznidazole in association with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi: investigation into the possible development of neoplasias.
dc.typeArticle
dc.description.abstractenBenznidazole is recommended in Brazil for the treatment of Trypanosoma cruzi infection in acute and early chronic phases of Chagas' disease. Observations by others have indicated a higher incidence of neoplasias in immunosuppressed patients, presenting Chagas' disease reactivation, submitted to treatment with benznidazole. In the present study, we investigated whether there is a potentiation in the generation of lymphomas in chronically infected mice, treated with immunosuppressive drugs and benznidazole. For this, 142 Swiss mice chronically infected with the 21 SF strain of T. cruzi and 72 normal Swiss mice were used. Both infected and normal mice were divided into experimental groups and submitted to one of the following treatment regimens: benznidazole alone; immunosuppressive drugs (azathioprine, betamethasone and cyclosporin); a combination of immunosuppressive drugs and benznidazole; and untreated controls. In the infected group treated with benznidazole, one mouse developed a non-Hodgkin's lymphoma. This finding has been interpreted as a spontaneous tumor of mice. The study of the chronically infected mice treated with the combination of immunosuppressive drugs and benznidazole demonstrated an absence of lymphomas or other neoplasias. These findings support the indication of benznidazole, as the drug of choice, for immunosuppressed patients that develop a reactivation of Chagas' disease.
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
dc.subject.enTrypanosoma cruzi
dc.subject.enExperimental Infection
dc.subject.enChemotherapy
dc.subject.enBenznidazole
dc.subject.enImmunosuppressive Drugs
dc.subject.enNon-Hodgkin’s lymphoma
dc.subject.decsDoença de Chagas/quimioterapia
dc.subject.decsImunossupressores/efeitos adversos
dc.subject.decsNeoplasias/induzido quimicamente
dc.subject.decsNitroimidazóis/efeitos adversos
dc.subject.decsTripanossomicidas/efeitos adversos
dc.subject.decsDoença Crônica
Appears in Collections:BA - IGM - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
Andrade SG Treatment with benznidazole....pdf159.8 kBAdobe PDFThumbnail
View/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.